gastroparesis and glp 1 drugs Drug-Induced Product Liability Incidence of Gastroparesis with GLP-1
Description
2014;103(3):e53e55
In 2024, the United States budgeted nearly $44.5 billion for drug control
The United States, in particular, represents a large market for GLP-1 receptor agonists, driven by the presence of key pharmaceutical players and high levels of healthcare investment
Glucagon-like peptide1 (GLP1) receptor agonists represent a powerful treatment option to aid in managing these complex conditions
Reported reductions in SBP ranged from approximately 1 to 3 mm Hg
Still, these perceptions are not static and may shift as confidence in oral approaches grows
